

Francesca Bergamo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6604428/publications.pdf>

Version: 2024-02-01

116
papers

4,139
citations

156536

32
h-index

145109

60
g-index

118
all docs

118
docs citations

118
times ranked

5998
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 161, 90-98.	1.3	13
2	Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise. <i>Oncologist</i> , 2022, 27, e158-e167.	1.9	3
3	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
4	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. , 2022, 10, e004001.		45
5	Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analysis of Tribe and Tribe-2 Studies by GONO. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	3
6	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O ⁶ -Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1562-1573.	0.8	52
7	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103647.	2.0	10
8	Negative Ultraselection of Patients With <i>RAS</i> / <i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy. <i>JCO Precision Oncology</i> , 2022, 6, e2200037.	1.5	11
9	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS</i> / <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
10	Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. <i>Tumori</i> , 2021, 107, 46-54.	0.6	2
11	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with <i>RAS</i> wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	1.3	12
12	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	1.3	8
13	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
14	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
15	Health-related quality of life in patients with <i>RAS</i> wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
16	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019, 9, 622.	1.3	22
17	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
18	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , 2019, 9, 11527.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019, 19, 455-464.	0.9	5
20	An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 635-644.	1.0	7
21	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	1.3	36
22	Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study. <i>Tumori</i> , 2019, 105, 243-252.	0.6	2
23	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	3.2	67
24	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
25	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	1.3	25
26	Another Chapter of the Right Versus Left Story : Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2019, 24, e77-e79.	1.9	3
27	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
28	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	3.4	280
29	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019, 42, 159-179.	1.4	18
30	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019, 42, 211-233.	1.4	76
31	Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3508-3508.	0.8	17
32	Neoadjuvant epirubicin, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4066-4066.	0.8	2
33	Immune senescence and immune activation in elderly colorectal cancer patients. <i>Aging</i> , 2019, 11, 3864-3875.	1.4	15
34	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 878-886.	2.9	20
35	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018, 36, 709-714.	1.2	8
36	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	3.4	87

#	ARTICLE	IF	CITATIONS
37	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 251-266.	1.1	41
38	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Annals of Oncology, 2018, 29, 924-930.	0.6	99
39	Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). Oncologist, 2018, 23, 912-918.	1.9	16
40	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. British Journal of Cancer, 2018, 118, 955-965.	2.9	17
41	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. Acta Oncologica, 2018, 57, 412-419.	0.8	2
42	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
43	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. BMC Cancer, 2018, 18, 98.	1.1	17
44	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. Oncology, 2018, 95, 344-352.	0.9	11
45	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The ATOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	1.0	18
46	NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS ONE, 2018, 13, e0193640.	1.1	5
47	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. Journal of Clinical Oncology, 2018, 36, 554-554.	0.8	39
48	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study. Journal of Clinical Oncology, 2018, 36, 581-581.	0.8	3
49	Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 2018, 36, 692-692.	0.8	1
50	<i>DPYD</i> and <i>UGT1A1</i> genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget, 2018, 9, 7859-7866.	0.8	25
51	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs. Journal of Clinical Oncology, 2018, 36, 636-636.	0.8	0
52	Abstract CT088: Efficacy of anti-EGFR rechallenge in <i>RAS</i> and <i>BRAF</i> wt metastatic colorectal cancer: Clinical and translational results of the phase II CRICKET study by GONO. Cancer Research, 2018, 78, CT088-CT088.	0.4	2
53	An untreatable dyspnoea: more defendants under investigation. Internal and Emergency Medicine, 2017, 12, 199-205.	1.0	0
54	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	1.3	54

#	ARTICLE	IF	CITATIONS
55	Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275.	1.1	10
56	Prediction of NO Irradiated Rectal Cancer Comparing MRI Before and After Preoperative Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 1184-1191.	0.7	13
57	Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 1269-1277.	2.9	55
58	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1297-1308.	1.4	21
59	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	2.0	10
60	Immunotherapy in Gastrointestinal Cancers. <i>BioMed Research International</i> , 2017, 2017, 1-17.	0.9	69
61	Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3542-3542.	0.8	3
62	Angiogenesis inhibitor bevacizumab and symptomatic anal ulcers in metastatic colorectal cancer patients: A single center experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15042-e15042.	0.8	0
63	Partial splenic embolization in chemotherapy-induced thrombocytopenia: A retrospective analysis with long term follow-up.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21654-e21654.	0.8	0
64	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) \geq 4 months (m). <i>Annals of Oncology</i> , 2016, 27, iv47.	0.6	1
65	TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). <i>Annals of Oncology</i> , 2016, 27, iv43.	0.6	0
66	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1482.	1.8	12
67	Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 877-885.	1.3	11
68	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
69	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
70	TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC). <i>Annals of Oncology</i> , 2016, 27, vi170.	0.6	1
71	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in <i>RAS</i> / <i>BRAF</i> wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. <i>Annals of Oncology</i> , 2016, 27, vi152.	0.6	3
72	Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. <i>Annals of Oncology</i> , 2016, 27, iv44.	0.6	0

#	ARTICLE	IF	CITATIONS
73	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016, 27, 843-849.	0.6	46
74	Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3540-3540.	0.8	1
75	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in <i>RAS</i>/<i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3543-3543.	0.8	9
76	Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4124-4124.	0.8	5
77	Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15149-e15149.	0.8	1
78	Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3635-TPS3635.	0.8	1
79	Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 733-733.	0.8	0
80	Induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC): The phase II TRUST trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 673-673.	0.8	0
81	Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3627-TPS3627.	0.8	0
82	NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11597-11597.	0.8	0
83	Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3615-3615.	0.8	0
84	P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. <i>Annals of Oncology</i> , 2015, 26, iv32.	0.6	1
85	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , 2015, 4, 6828.	1.6	31
86	BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015, 112, 1921-1928.	2.9	146
87	Single-Agent Panitumumab in Frail Elderly Patients With Advanced <i>RAS</i> and <i>BRAF</i> Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015, 20, 1261-1265.	1.9	42
88	A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 315-321.	0.3	28
89	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 2503.	0.6	18
90	Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	2.3	126

#	ARTICLE	IF	CITATIONS
91	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3532-3532.	0.8	2
92	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. Journal of Clinical Oncology, 2015, 33, 412-412.	0.8	4
93	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A "real-life" study.. Journal of Clinical Oncology, 2015, 33, 424-424.	0.8	10
94	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657.	0.8	17
95	Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (MO) colorectal cancer (CRC)?. Journal of Clinical Oncology, 2015, 33, 650-650.	0.8	0
96	Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. British Journal of Cancer, 2014, 111, 25-32.	2.9	41
97	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology, 2014, 25, 1373-1378.	0.6	84
98	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. Journal of the Peripheral Nervous System, 2014, 19, 299-306.	1.4	67
99	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	2.9	69
100	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 57-63.	1.3	162
101	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). World Journal of Surgical Oncology, 2014, 12, 46.	0.8	33
102	Phase II Study of Single Agent Cetuximab in Kras G13D Mutant Metastatic Colorectal Cancer (MCRC). Annals of Oncology, 2014, 25, ii6.	0.6	1
103	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3524-3524.	0.8	6
104	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology, 2014, 32, TPS3664-TPS3664.	0.8	2
105	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 476-476.	0.8	0
106	Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heavily pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis.. Journal of Clinical Oncology, 2014, 32, e15255-e15255.	0.8	0
107	Clinical pattern and associations of oxaliplatin acute neurotoxicity. Cancer, 2013, 119, 438-444.	2.0	179
108	Ultrasound assessment of oxaliplatin-induced neuropathy and correlations with neurophysiologic findings. European Journal of Neurology, 2013, 20, 188-192.	1.7	26

#	ARTICLE	IF	CITATIONS
109	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial. <i>European Journal of Cancer</i> , 2013, 49, 3609-3615.	1.3	76
110	FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013, 24, 2062-2067.	0.6	86
111	Corneal confocal microscopy in patients with oxaliplatin-induced peripheral neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2013, 18, 269-271.	1.4	23
112	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
113	Hepatoid Adenocarcinoma of the Colon: What Should We Target?. <i>Pathology and Oncology Research</i> , 2012, 18, 93-96.	0.9	26
114	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 81, 38-48.	2.0	30
115	Chemotherapy for operable and advanced colorectal cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 509-516.	3.4	17
116	Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6